JPMorgan Chase & Co. Issues Positive Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its target price raised by JPMorgan Chase & Co. from $250.00 to $270.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the conglomerate’s stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 14.78% from the stock’s previous close.

A number of other research analysts have also commented on the stock. Citigroup restated a “buy” rating on shares of Danaher in a research report on Thursday. Royal Bank Of Canada increased their price objective on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Sunday. The Goldman Sachs Group reissued a “buy” rating on shares of Danaher in a research note on Thursday. Finally, UBS Group initiated coverage on Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $239.50.

Danaher Trading Up 0.6%

Shares of Danaher stock opened at $235.23 on Thursday. Danaher has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a market cap of $165.37 billion, a price-to-earnings ratio of 41.80, a PEG ratio of 2.82 and a beta of 0.76. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $215.25 and its 200-day moving average price is $196.84.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating the consensus estimate of $1.92 by $0.19. The company had revenue of $6.55 billion during the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.89 earnings per share. On average, equities analysts expect that Danaher will post 8.53 earnings per share for the current fiscal year.

Institutional Trading of Danaher

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Danaher during the 2nd quarter worth $10,492,520,000. Wellington Management Group LLP increased its stake in Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after acquiring an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC purchased a new stake in Danaher during the second quarter valued at about $1,456,317,000. Generation Investment Management LLP purchased a new stake in Danaher during the second quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE purchased a new stake in Danaher during the second quarter valued at about $993,846,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, well above the $1.92 consensus estimate. Revenue rose 8.3% year over year to $6.55 billion, essentially in line with expectations, while stronger Biotechnology profitability supported margin expansion. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, above the prior outlook and analyst expectations. Biotechnology orders grew at a mid-teens rate, suggesting improving customer demand and a potentially stronger recovery across key end markets. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Analysts became more constructive following the results. Stifel Nicolaus raised its price target from $220 to $260 and upgraded DHR to Buy, while Robert W. Baird lifted its target from $246 to $254 and assigned an Outperform rating. Goldman Sachs also increased its target to $275 from $250. Goldman Sachs Adjusts Price Target on Danaher
• Positive Sentiment: Management highlighted artificial-intelligence capabilities as a longer-term growth opportunity in drug discovery, while the Masimo acquisition helped offset weakness in respiratory diagnostic sales. Danaher says it has building blocks for AI drug discovery growth

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.